On 12- 14 November 2019 ReSViNET Foundation heldt its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. We look back on a successful, exciting and inspiring meeting. Our special thanks to our sponsors to make this event possible and our chairs and scientific advisory board. Last but not least we thank all the speakers and participants for their contributions. |
Recent developments in RSV InterventionsInterested in the recent developments of RSV? Then register for our free webinar on December 12th 6 pm: https://lnkd.in/duTsJYQ . Prof. Louis Bont and Dr. Natalie mazur will give a full summary of the highlights of the #RSVVW19 conference in Accra. Make sure to register to join the webinar and receive a replay afterwards by e-mail. https://lnkd.in/duTsJYQ |
AWARENESS OF RSV AS A GLOBAL HEALTH PROBLEM IS LACKING
|
To raise and spread awareness, we have launched a ‘RSV Mortality Awareness’ campaign at the start of the RSVVW2019 conference on November 12, by sharing a personal video entitled “Why we should all know about RSV” about Simone van Wyck, a mother who lost her son due to RSV. The RSV awareness video was produced in collaboration with the Bill & Melinda Gates Foundation.
|
|
PAPER OF THE MONTH - November 2019
RSV/NS2/1313/I1314L vaccine in RSV-seronegative children is safe and immunogenic
Ruth A. Karron,1 Cindy Luongo,2 Jocelyn San Mateo,1 Kimberli Wanionek,1 Peter L. Collins,2 Ursula J. Buchholz,2 and the RSVPed Team
The RSV/NS2/1313/I1314L is an intranasal vaccine that contains two attenuating elements in the RSV strain: deletion of the NS2 gene and deletion of the codon 1313. The deletions are stabilized with the substitution of isoleucine at codon 1314. This vaccine induced an immunogenic response in nonhuman primates. A phase 1 double-blind, randomized, placebo-controlled trial was conducted at the Center for Immunization Research (CIR) between 2013 and 2018 in RSV-seronegative and RSV-seropositive children aged 12-59 months. RSV-seronegative children received a single dose of 10 5 or 10 6 PFU and RSV-seropositive children received a single dose of 10 6 PFU. The authors demonstrated that none of the RSV-seropositive children had a ≥4-fold rise in RSV F serum IgG titer. By contrast, 53% of RSV-seronegative children who received 10 5 PFU, developed RSV neutralizing antibodies and F
IgG responses. In RSV-seronegative children receiving 10 6 PFU, even 80% developed RSV neutralizing antibodies and a similar rise in RSV-F IgG antibodies. This indicates that the RSV vaccine is a proper and genetically stable candidate in RSV-seronegative children, which deserves further clinical evaluation in seronegative children.
This review was written by Safia Laqqa under the supervision of Louis Bont
Ruth A. Karron,1 Cindy Luongo,2 Jocelyn San Mateo,1 Kimberli Wanionek,1 Peter L. Collins,2 Ursula J. Buchholz,2 and the RSVPed Team
The RSV/NS2/1313/I1314L is an intranasal vaccine that contains two attenuating elements in the RSV strain: deletion of the NS2 gene and deletion of the codon 1313. The deletions are stabilized with the substitution of isoleucine at codon 1314. This vaccine induced an immunogenic response in nonhuman primates. A phase 1 double-blind, randomized, placebo-controlled trial was conducted at the Center for Immunization Research (CIR) between 2013 and 2018 in RSV-seronegative and RSV-seropositive children aged 12-59 months. RSV-seronegative children received a single dose of 10 5 or 10 6 PFU and RSV-seropositive children received a single dose of 10 6 PFU. The authors demonstrated that none of the RSV-seropositive children had a ≥4-fold rise in RSV F serum IgG titer. By contrast, 53% of RSV-seronegative children who received 10 5 PFU, developed RSV neutralizing antibodies and F
IgG responses. In RSV-seronegative children receiving 10 6 PFU, even 80% developed RSV neutralizing antibodies and a similar rise in RSV-F IgG antibodies. This indicates that the RSV vaccine is a proper and genetically stable candidate in RSV-seronegative children, which deserves further clinical evaluation in seronegative children.
This review was written by Safia Laqqa under the supervision of Louis Bont
|
Neeltje from The Netherlands, 99 years old, participant of the RESCEU Older adults study. RSV is an important cause of pneumonia in older adults. Awareness of RSV in older adults is almost absent. Every year about 3-6% of all older adults are infected with RSV. Course of disease is most severe on older adults with severe underlying disease such as heart failure or COPD.
|
ABOUT RESVINET FOUNDATIONRSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. |
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!
|
ReSViNET Global partners
